


AMENDMENTS TO THE CLAIMS – Marked Up Version

Claims 1-96 are pending.

The following list of claims will replace prior versions and listing of claims in the application:

1. (Currently Amended) A compound of formula (I)



or a pharmaceutically acceptable salt or ~~prodrug~~ thereof, wherein


X is selected from the group consisting of O and NR_A;

R_A is selected from the group consisting of hydrogen and alkyl;

R₁ is selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkynyl, arylalkyl, cyanoalkyl, cycloalkyl, haloalkyl, and hydroxyalkyl;

R₂ is selected from the group consisting of aryl, arylalkyl, heteroaryl, and heteroarylalkyl; wherein the heteroaryl and the heteroaryl moiety of the heteroarylalkyl are monocyclic, five or six membered rings containing 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S;

R₃ is selected from the group consisting of




R₄ is heteroaryl wherein the heteroaryl is a monocyclic, five or six membered ring containing 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S;

L is C₁-C₂ alkylene substituted with 0 or 1 substituent selected from the group consisting of alkoxy, alkoxyamino, hydroxy, and hydroxyiminoaryl;

R_B is selected from the group consisting of ~~hydrogen and alkyl~~;

~~Z is selected from the group consisting of C, CH, and N; and
--- is absent or a single bond provided that when --- is a single bond then Z is C.~~

2. (Cancelled) The compound according to claim 1 wherein R₃ is



3. (Currently Amended) The compound according to claim 2 1 wherein

X is O;

R₂ is aryl;

~~Z is N;~~

~~--- is absent; and~~

R₄ is heteroaryl.

4. (Currently Amended) The compound according to claim 2 1 wherein

X is O;

R₂ is aryl wherein the aryl is selected from the group consisting of naphthyl and phenyl wherein the phenyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkyl, cyano, and halogen;

~~Z is N;~~

~~--- is absent; and~~

R₄ is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

5. (Currently Amended) The compound according to claim 4 selected from the group consisting of

(1E)-1-(3-chlorophenyl)-3-(4-pyridin-2-yl-piperazin-1-yl)propan-1-one O-methyloxime;

(1Z)-1-(3-chlorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1E)-1-(4-chlorophenyl)-3-(4-pyridin-2-yl-piperazin-1-yl)propan-1-one O-methyloxime;

(1Z)-1-(4-chlorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1E)-1-(4-fluorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)ethanone O-methyloxime;

(1Z)-1-(4-fluorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)ethanone O-methyloxime;

(1E)-1-(4-chlorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)ethanone O-methyloxime;

(1Z)-1-(4-chlorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)ethanone O-methyloxime;

(1E)-1-(3,4-dimethylphenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1Z)-1-(3,4-dimethylphenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1E)-1-(3-chloro-4-fluorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1Z)-1-(3-chloro-4-fluorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1E)-1-(3-methylphenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1Z)-1-(3-methylphenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1E)-1-(4-fluorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1Z)-1-(4-fluorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1E)-1-(3,4-dichlorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)ethanone O-methyloxime;

(1Z)-1-(3,4-dichlorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)ethanone O-methyloxime;

(1E)-1-(2-methylphenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-ethyloxime;

(1Z)-1-(2-methylphenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-ethyloxime;

(1E)-1-(2-methylphenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1Z)-1-(2-methylphenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

3-[(1E)-N-methoxy-3-(4-pyridin-2-ylpiperazin-1-yl)propanimidoyl]benzonitrile

3-[(1Z)-N-methoxy-3-(4-pyridin-2-ylpiperazin-1-yl)propanimidoyl]benzonitrile

(1E)-1-(2,4-dichlorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)ethanone O-methyloxime;

(1Z)-1-(2,4-dichlorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)ethanone O-methyloxime;

(1E)-1-phenyl-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one oxime;

(1Z)-1-phenyl-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one oxime;

~~1,5-diphenyl-2-[(4-pyridin-2-yl)piperazin-1-yl]methyl]pentane-1,5-dione dioxime;~~

(1E)-1-phenyl-3-(4-pyrimidin-2-ylpiperazin-1-yl)propan-1-one oxime;

(1Z)-1-phenyl-3-(4-pyrimidin-2-ylpiperazin-1-yl)propan-1-one oxime;

~~1,5-diphenyl-2-[(4-pyrimidin-2-yl)piperazin-1-yl]methyl]pentane-1,5-dione dioxime;~~

1-(4-fluorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one oxime;

(1E)-1-(4-chlorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one oxime;

(1E)-1-phenyl-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-ethyloxime;

(1Z)-1-phenyl-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-ethyloxime;

(1E)-1-phenyl-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1Z)-1-phenyl-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1E)-1-phenyl-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-propyloxime;
(1Z)-1-phenyl-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-propyloxime;
(1E)-1-phenyl-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-allyloxime;
(1Z)-1-phenyl-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-allyloxime;
(1E)-1-(3,5-difluorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;
(1Z)-1-(3,5-difluorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;
({{1-phenyl-3-(4-pyridin-2-ylpiperazin-1-yl)propylidene]amino}oxy)acetonitrile;
1-phenyl-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-butyloxime;
(1E)-1-phenyl-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-isopropyloxime;
(1E)-1-(3,5-dimethylphenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;
(1Z)-1-(3,5-dimethylphenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;
(1E)-1-(4-chloro-3-methylphenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;
(1Z)-1-(4-chloro-3-methylphenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;
(1E)-1-(2-naphthyl)-2-(4-pyridin-2-ylpiperazin-1-yl)ethanone O-methyloxime;
(1Z)-1-(2-naphthyl)-2-(4-pyridin-2-ylpiperazin-1-yl)ethanone O-methyloxime;
(1E)-1-(3-methylphenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-ethyloxime;
(1Z)-1-(3-methylphenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-ethyloxime;
1-(4-fluorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-(2,2,2-trifluoroethyl)oxime;
1-(4-chlorophenyl)-3-(methoxyamino)-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]propan-1-one O-methyloxime;
1-(4-chlorophenyl)-3-isopropoxy-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]propan-1-one O-methyloxime;

1-(4-chlorophenyl)-2-methyl-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1E)-1-(3,4-dichlorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1Z)-1-(3,4-dichlorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1E)-1-(2-chlorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1Z)-1-(2-chlorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1E)-1-(2,4-dichlorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1Z)-1-(2,4-dichlorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1E)-1-(4-bromophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1Z)-1-(4-bromophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1E)-1-(3-fluorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1Z)-1-(3-fluorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime;

(1E)-1-(4-fluorophenyl)-2-(4-pyrimidin-2-ylpiperazin-1-yl)ethanone oxime;

(1Z)-1-(4-fluorophenyl)-2-(4-pyrimidin-2-ylpiperazin-1-yl)ethanone oxime;

(1E)-1-(4-fluorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)ethanone oxime;

(1Z)-1-(4-fluorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)ethanone oxime;

2-{4-[(3E)-3-(hydroxyimino)-3-phenylpropyl]piperazin-1-yl}nicotinonitrile;

2-{4-[(3Z)-3-(hydroxyimino)-3-phenylpropyl]piperazin-1-yl}nicotinonitrile;

1-phenyl-3-[4-(1,3-thiazol-2-yl)piperazin-1-yl]propan-1-one oxime;

1-phenyl-3-(4-pyrimidin-2-ylpiperazin-1-yl)propan-1-one O-ethyloxime;

1-phenyl-3-[4-(1,3-thiazol-2-yl)piperazin-1-yl]propan-1-one O-ethyloxime;

3-[4-(3-methylpyridin-2-yl)piperazin-1-yl]-1-phenylpropan-1-one O-ethyloxime;
2-{4-[3-(ethoxyimino)-3-phenylpropyl]piperazin-1-yl}nicotinonitrile;
2-{4-[3-(ethoxyimino)-3-(3-methylphenyl)propyl]piperazin-1-yl}nicotinonitrile;
(1E)-1-(4-fluorophenyl)-2-[(2S)-2-methyl-4-pyridin-2-ylpiperazin-1-yl]ethanone
O-methyloxime;
(1Z)-1-(4-fluorophenyl)-2-[(2S)-2-methyl-4-pyridin-2-ylpiperazin-1-yl]ethanone
O-methyloxime;
(1E)-1-(4-chlorophenyl)-3-[(2S)-2-methyl-4-pyridin-2-ylpiperazin-1-yl]propan-1-
one O-methyloxime;
(1Z)-1-(4-chlorophenyl)-3-[(2S)-2-methyl-4-pyridin-2-ylpiperazin-1-yl]propan-1-
one O-methyloxime;
1-(4-chlorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-(2-
hydroxyethyl)oxime;
(1E)-1-(4-chlorophenyl)-3-[4-(5-hydroxypyridin-2-yl)piperazin-1-yl]propan-1-
one O-methyloxime;
(1Z)-1-(4-chlorophenyl)-3-[4-(5-hydroxypyridin-2-yl)piperazin-1-yl]propan-1-
one O-methyloxime;
1-(4-fluorophenyl)-2-[4-(5-hydroxypyridin-2-yl)piperazin-1-yl]ethanone O-
methyloxime;
(1E)-1-(4-chlorophenyl)-2-hydroxy-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one
O-methyloxime;
(1Z)-1-(4-chlorophenyl)-2-hydroxy-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one
O-methyloxime;
(1E)-1-(4-chlorophenyl)-3-(4-pyrimidin-2-ylpiperazin-1-yl)propan-1-one O-
methyloxime;
(1Z)-1-(4-chlorophenyl)-3-(4-pyrimidin-2-ylpiperazin-1-yl)propan-1-one O-
methyloxime;
(1E)-1-(4-chlorophenyl)-2-methoxy-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one
O-methyloxime; and
(1Z)-1-(4-chlorophenyl)-2-methoxy-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one
O-methyloxime.

6. (Currently Amended) The compound according to claim 2 1 wherein

X is O;

R₂ is arylalkyl;

~~Z is N;~~

~~— is absent;~~ and

R₄ is heteroaryl.

7. (Currently Amended) The compound according to claim 2 1 wherein

X is O;

R₂ is arylalkyl wherein the arylalkyl is benzyl;

~~Z is N;~~

~~— is absent;~~ and

R₄ is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

8. (Original) The compound according to claim 7 selected from the group consisting of

(2E)-1-phenyl-3-(4-pyridin-2-ylpiperazin-1-yl)acetone O-methyloxime; and

(2Z)-1-phenyl-3-(4-pyridin-2-ylpiperazin-1-yl)acetone O-methyloxime.

9. (Currently Amended) The compound according to claim 2 1 wherein

X is O;

R₂ is heteroaryl;

~~Z is N;~~

~~— is absent;~~ and

R₄ is heteroaryl.

10. (Currently Amended) The compound according to claim 2 1 wherein

X is O;

R₂ is heteroaryl wherein the heteroaryl is pyridin-3-yl;

Z is N;

— is absent; and

R_4 is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

11. (Original) The compound according to claim 4 selected from the group consisting of

(1E)-1-pyridin-3-yl-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime; and

(1Z)-1-pyridin-3-yl-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime.

12. (Withdrawn) The compound according to claim 2 wherein

X is O;

R_2 is aryl;

Z is C;

--- is a single bond; and

R_4 is heteroaryl.

13. (Withdrawn) The compound according to claim 2 wherein

X is O;

R_2 is aryl wherein the aryl is selected from the group consisting of naphthyl and phenyl wherein the phenyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkyl, cyano, and halogen;

Z is C;

--- is a single bond; and

R_4 is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

14. (Withdrawn) The compound according to claim 13 selected from the group consisting of

1-(4-fluorophenyl)-3-[4-(1,3-thiazol-2-yl)-3,6-dihdropyridin-1(2H)-yl]propan-1-one O-methyloxime;

(1E)-1-(4-chlorophenyl)-2-[4-(1,3-thiazol-2-yl)-3,6-dihdropyridin-1(2H)-yl]ethanone O-methyloxime;

(1Z)-1-(4-chlorophenyl)-2-[4-(1,3-thiazol-2-yl)-3,6-dihdropyridin-1(2H)-yl]ethanone O-methyloxime;

(1E)-1-(4-chlorophenyl)-3-(3-methyl-3',6'-dihydro-2,4'-bipyridin-1'(2'H)-yl)propan-1-one O-methyloxime; and

(1Z)-1-(4-chlorophenyl)-3-(3-methyl-3',6'-dihydro-2,4'-bipyridin-1'(2'H)-yl)propan-1-one O-methyloxime.

15. (Withdrawn) The compound according to claim 2 wherein

X is O;

R₂ is aryl;

Z is CH;

--- is absent; and

R₄ is heteroaryl.

16. (Withdrawn) The compound according to claim 2 wherein

X is O;

R₂ is aryl wherein the aryl is selected from the group consisting of naphthyl and phenyl wherein the phenyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkyl, cyano, and halogen;

Z is CH;

--- is absent; and

R₄ is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

17. (Withdrawn) The compound according to claim 16 selected from the group consisting of

(1E)-1-(4-chlorophenyl)-3-(4-pyridin-2-ylpiperidin-1-yl)propan-1-one O-methyloxime;

(1Z)-1-(4-chlorophenyl)-3-(4-pyridin-2-ylpiperidin-1-yl)propan-1-one O-methyloxime;

2- $\{1-[(3E)-3-(4-chlorophenyl)-3-(methoxyimino)propyl]piperidin-4-yl\}$ pyridinium N-oxide;

2- $\{1-[(3Z)-3-(4-chlorophenyl)-3-(methoxyimino)propyl]piperidin-4-yl\}$ pyridinium N-oxide;

2- $\{1-[(2E)-2-(4-fluorophenyl)-2-(methoxyimino)ethyl]piperidin-4-yl\}$ pyridinium N-oxide; and

2- $\{1-[(2Z)-2-(4-fluorophenyl)-2-(methoxyimino)ethyl]piperidin-4-yl\}$ pyridinium N-oxide.

18. (Currently Amended) The compound according to claim 2 1 wherein

X is NR_A;

R₂ is aryl;

~~Z is N;~~

~~_____ is absent;~~ and

R₄ is heteroaryl.

19. (Currently Amended) The compound according to claim 2 1 wherein

X is NR_A;

R₂ is aryl wherein the aryl is selected from the group consisting of naphthyl and phenyl wherein the phenyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkyl, cyano, and halogen;

~~Z is N;~~

~~_____ is absent;~~ and

R_4 is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

20. (Original) The compound according to claim 19 that is 1-(4-fluorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)ethanone methylhydrazone.

21. (Withdrawn) The compound according to claim 2 wherein

X is NR_A ;

R_2 is aryl;

Z is CH;

--- is absent; and

R_4 is heteroaryl.

22. (Withdrawn) The compound according to claim 2 wherein

X is NR_A ;

R_2 is aryl wherein the aryl is selected from the group consisting of naphthyl and phenyl wherein the phenyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkyl, cyano, and halogen;


Z is CH;

--- is absent; and

R_4 is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

23. (Withdrawn) The compound according to claim 22 that is 1-(4-fluorophenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)ethanone methylhydrazone.

24. (Withdrawn) The compound according to claim 1 wherein R_3 is



25. (Withdrawn) The compound according to claim 24 wherein

R₂ is aryl; and

R₄ is heteroaryl.

26. (Withdrawn) The compound according to claim 24 wherein

R₂ is aryl wherein the aryl is selected from the group consisting of naphthyl and phenyl wherein the phenyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkyl, cyano, and halogen; and

R₄ is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

27. (Withdrawn) The compound according to claim 26 selected from the group consisting of

1-(4-fluorophenyl)-3-[3-(1,3-thiazol-2-yl)piperidin-1-yl]propan-1-one O-methyloxime;

1-(4-fluorophenyl)-3-[3-(1,3-thiazol-2-yl)piperidin-1-yl]propan-1-one O-ethyloxime;

1-(4-fluorophenyl)-3-(3-pyridin-2-ylpiperidin-1-yl)propan-1-one O-methyloxime;

1-(4-chlorophenyl)-3-(3-pyridin-2-ylpiperidin-1-yl)propan-1-one O-methyloxime;


(1E)-1-(4-chlorophenyl)-3-[3-(1,3-thiazol-2-yl)piperidin-1-yl]propan-1-one O-methyloxime;

(1Z)-1-(4-chlorophenyl)-3-[3-(1,3-thiazol-2-yl)piperidin-1-yl]propan-1-one O-methyloxime;

2-{1-[2-(4-fluorophenyl)-2-(methoxyimino)ethyl]piperidin-3-yl}pyridinium N-oxide; and

2-{1-[3-(4-fluorophenyl)-3-(methoxyimino)propyl]piperidin-3-yl}pyridinium N-oxide.

28. (Withdrawn) The compound according to claim 1 wherein R_3 is



29. (Withdrawn) The compound according to claim 28 wherein
 R_2 is aryl; and
 R_4 is heteroaryl.

30. (Withdrawn) The compound according to claim 28 wherein
 R_2 is aryl wherein the aryl is selected from the group consisting of naphthyl and phenyl wherein the phenyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkyl, cyano, and halogen; and
 R_4 is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

31. (Withdrawn) The compound according to claim 30 selected from the group consisting of

(1E)-1-(4-fluorophenyl)-3-(3-pyrazin-2-ylpyrrolidin-1-yl)propan-1-one O-methyloxime;

(1Z)-1-(4-fluorophenyl)-3-(3-pyrazin-2-ylpyrrolidin-1-yl)propan-1-one O-methyloxime;

(1E)-1-(4-fluorophenyl)-2-(3-pyrazin-2-ylpyrrolidin-1-yl)ethanone O-methyloxime;

(1Z)-1-(4-fluorophenyl)-2-(3-pyrazin-2-ylpyrrolidin-1-yl)ethanone O-methyloxime;

(1E)-1-(4-fluorophenyl)-3-(3-pyrazin-2-ylpyrrolidin-1-yl)propan-1-one oxime;

(1Z)-1-(4-fluorophenyl)-3-(3-pyrazin-2-ylpyrrolidin-1-yl)propan-1-one oxime;
and

(1Z)-1-(4-fluorophenyl)-2-(3-pyrazin-2-ylpyrrolidin-1-yl)ethanone oxime.

32. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1 in combination with a pharmaceutically acceptable carrier.

33. (Currently Amended) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt or prodrug thereof in combination with a pharmaceutically acceptable carrier.

34. (Currently Amended) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.

35. (Currently Amended) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt or prodrug thereof in combination with an adrenergic receptor antagonist.

36. (Currently Amended) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt or prodrug thereof in combination with a dopamine agonist.


37. (Currently Amended) A method of treating male erectile dysfunction in a mammal comprising administering to the mammal in need of such treatment a

therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt or ~~prodrug~~ thereof.

38. (Currently Amended) A method of treating female sexual dysfunction in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt or ~~prodrug~~ thereof.

39. (Withdrawn) A method of treating cardiovascular disorders, inflammatory disorders, attention deficit hyperactivity disorder, Alzheimer's disease, drug abuse, Parkinson's disease, schizophrenia, anxiety, mood disorders or depression in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof.

40. (Currently Amended) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (Ia)



(Ia)

or a pharmaceutically acceptable salt or ~~prodrug~~ thereof, wherein

X is selected from the group consisting of O and NR_A;


R_A is selected from the group consisting of hydrogen and alkyl;

R₁ is selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkynyl, arylalkyl, cyanoalkyl, cycloalkyl, haloalkyl, and hydroxyalkyl;

R₂ is selected from the group consisting of aryl, arylalkyl, heteroaryl, and heteroarylalkyl; wherein the heteroaryl and the heteroaryl moiety of the heteroarylalkyl

are monocyclic, five or six membered rings containing 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S;

R₃ is selected from the group consisting of



R₄ is heteroaryl; wherein the heteroaryl is a monocyclic, five or six membered ring containing 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S;


L is alkylene substituted with 0 or 1 substituent selected from the group consisting of alkoxy, alkoxyamino, hydroxy, and hydroxyiminoaryl;

R_B is selected from the group consisting of hydrogen and alkyl;

Z is selected from the group consisting of C, CH, and N; and

--- is absent or a single bond provided that when --- is a single bond then Z is C; or a pharmaceutically acceptable salt or prodrug thereof in combination with a pharmaceutically acceptable carrier.

41. (Cancelled) The method according to claim 40 wherein R₃ is



42. (Currently Amended) The method according to claim 41 40 wherein

X is O;

R₂ is aryl;

Z is N;

--- is absent; and

R₄ is heteroaryl.

43. (Currently Amended) The method according to claim 41 40 wherein

X is O;

R_2 is aryl wherein the aryl is selected from the group consisting of naphthyl and phenyl wherein the phenyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkyl, cyano, and halogen;

~~Z is N;~~

~~_____ is absent;~~ and

R_4 is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

44. (Currently Amended) The method according to claim 43 where the compound of formula (Ia) is selected from the group consisting of

(1E)-1-(4-fluorophenyl)-4-(4-pyridin-2-ylpiperazin-1-yl)butan-1-one oxime;

(1Z)-1-(4-fluorophenyl)-4-(4-pyridin-2-ylpiperazin-1-yl)butan-1-one oxime;

(1E)-1-(4-fluorophenyl)-4-(4-pyridin-2-ylpiperazin-1-yl)butan-1-one methyloxime; and

(1E)-1-(4-fluorophenyl)-4-(4-pyridin-2-ylpiperazin-1-yl)butan-1-one methyloxime.

45. (Currently Amended) The method according to claim 44 40 wherein

X is O;

R_2 is arylalkyl;

~~Z is N;~~

~~_____ is absent;~~ and

R_4 is heteroaryl.

46. (Currently Amended) The method according to claim 44 40 wherein

X is O;

R_2 is arylalkyl wherein the arylalkyl is benzyl;

~~Z is N;~~

~~_____ is absent;~~ and

R_4 is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

47. (Currently Amended) The method according to claim 41 40 wherein

X is O;

R_2 is heteroaryl;

Z is N;

~~—~~ is absent; and

R_4 is heteroaryl.

48. (Currently Amended) The method according to claim 41 40 wherein

X is O;

R_2 is heteroaryl wherein the heteroaryl is pyridin-3-yl;

Z is N;

~~—~~ is absent; and

R_4 is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

49. (Withdrawn) The method according to claim 41 wherein

X is O;

R_2 is aryl;

Z is C;

--- is a single bond; and

R_4 is heteroaryl.

50. (Withdrawn) The method according to claim 41 wherein

X is O;

R_2 is aryl wherein the aryl is selected from the group consisting of naphthyl and phenyl wherein the phenyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkyl, cyano, and halogen;

Z is C;

--- is a single bond; and

R_4 is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

51. (Withdrawn) The method according to claim 41 wherein

X is O;

R_2 is aryl;

Z is CH;

--- is absent; and

R_4 is heteroaryl.

52. (Withdrawn) The method according to claim 41 wherein

X is O;

R_2 is aryl wherein the aryl is selected from the group consisting of naphthyl and phenyl wherein the phenyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkyl, cyano, and halogen;

Z is CH;

--- is absent; and

R_4 is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

53. (Currently Amended) The method according to claim 41 40 wherein

X is NR_A ;

R_2 is aryl;

Z is N;

_____ is absent; and

R₄ is heteroaryl.

54. (Currently Amended) The method according to claim 41 40 wherein

X is NR_A;

R₂ is aryl wherein the aryl is selected from the group consisting of naphthyl and phenyl wherein the phenyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkyl, cyano, and halogen;

Z is N;

_____ is absent; and

R₄ is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

55. (Withdrawn) The method according to claim 41 wherein

X is NR_A;

R₂ is aryl;

Z is CH;

--- is absent; and

R₄ is heteroaryl.

56. (Withdrawn) The method according to claim 41 wherein

X is NR_A;


R₂ is aryl wherein the aryl is selected from the group consisting of naphthyl and phenyl wherein the phenyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkyl, cyano, and halogen;

Z is CH;

--- is absent; and

R₄ is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

57. (Withdrawn) The method according to claim 41 wherein R_3 is



58. (Withdrawn) The method according to claim 57 wherein

R_2 is aryl; and


R_4 is heteroaryl.

59. (Withdrawn) The method according to claim 57 wherein

R_2 is aryl wherein the aryl is selected from the group consisting of naphthyl and phenyl wherein the phenyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkyl, cyano, and halogen; and

R_4 is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

60. (Withdrawn) The method according to claim 40 wherein R_3 is



61. (Withdrawn) The method according to claim 60 wherein

R_2 is aryl; and


R_4 is heteroaryl.

62. (Withdrawn) The method according to claim 60 wherein

R_2 is aryl wherein the aryl is selected from the group consisting of naphthyl and phenyl wherein the phenyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkyl, cyano, and halogen; and

R_4 is heteroaryl wherein the heteroaryl is selected from the group consisting of pyrazin-2-yl, 3-cyanopyridin-2-yl, 5-hydroxypyridin-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl, 2-pyridinium N-oxide, pyrimidin-2-yl, and thiazol-2-yl.

63. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (Ia)



(Ia)

or a pharmaceutically acceptable salt thereof, wherein


X is selected from the group consisting of O and NR_A;

R_A is selected from the group consisting of hydrogen and alkyl;

R₁ is selected from the group consisting of hydrogen, alkoxyalkyl, alkyl, alkynyl, arylalkyl, cyanoalkyl, cycloalkyl, haloalkyl, and hydroxyalkyl;

R₂ is selected from the group consisting of aryl, arylalkyl, heteroaryl, and heteroarylalkyl; wherein the heteroaryl and the heteroaryl moiety of the heteroarylalkyl are monocyclic, five or six membered rings containing 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S;

R_3 is



R₄ is heteroaryl; wherein the heteroaryl is a monocyclic, five or six membered ring containing 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S;

L is alkylene substituted with 0 or 1 substituent selected from the group consisting of alkoxy, alkoxyamino, hydroxy, and hydroxyiminoaryl;

R_B is alkyl:

Z is N· and

--- is absent:

in combination with a pharmaceutically acceptable carrier.

64. (Cancelled) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof in combination with a pharmaceutically acceptable carrier.

65. (Currently Amended) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (Ia) according to claim 40 or a pharmaceutically acceptable salt ~~or prodrug~~ thereof in combination with a phosphodiesterase 5 inhibitor.

66. (Currently Amended) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (Ia) according to claim 40 or a pharmaceutically acceptable salt ~~or prodrug~~ thereof in combination with an adrenergic receptor antagonist.


67. (Currently Amended) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (Ia) according to claim 40 or a pharmaceutically acceptable salt ~~or prodrug~~ thereof in combination with a dopamine agonist.

68. (Currently Amended) A method of treating male erectile dysfunction in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (Ia) according to claim 40 or a pharmaceutically acceptable salt ~~or prodrug~~ thereof.

69. (Currently Amended) A method of treating female sexual dysfunction in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (Ia) according to claim 40 or a pharmaceutically acceptable salt ~~or prodrug~~ thereof.

70. (Withdrawn) A method of treating cardiovascular disorders, attention deficit hyperactivity disorder, Alzheimer's disease, drug abuse, Parkinson's disease, schizophrenia, anxiety, mood disorders or depression in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (Ia) or a pharmaceutically acceptable salt or prodrug thereof.

71. (Withdrawn) A compound of formula (II)



(II)

or a pharmaceutically acceptable salt or prodrug thereof, wherein


X is selected from the group consisting of O and NR_A ;

R_A is selected from the group consisting of hydrogen and alkyl;

R_1 is selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkynyl, arylalkyl, cyanoalkyl, cycloalkyl, haloalkyl, and hydroxyalkyl;

R_2 is selected from the group consisting of aryl, arylalkyl, heteroaryl, and heteroarylalkyl;

R_3 is selected from the group consisting of




R_4 is aryl;

L is alkylene substituted with 0 or 1 substituent selected from the group consisting of alkoxy, alkoxyamino, hydroxy, and hydroxyiminoaryl; and

R_B is selected from the group consisting of hydrogen and alkyl.

72. (Withdrawn) The compound according to claim 70 wherein R_3 is



73. (Withdrawn) The compound according to claim 72 wherein

R_2 is aryl; and

R_4 is aryl.

74. (Withdrawn) The compound according to claim 72 wherein

R_2 is aryl wherein the aryl is selected from the group consisting of naphthyl and phenyl wherein the phenyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkyl, cyano, and halogen; and

R_4 is aryl wherein the aryl is phenyl substituted with 0 or 1 substituent selected from the group consisting of alkoxy, cyano, and haloalkyl.

75. (Withdrawn) The compound according to claim 74 selected from the group consisting of

(1E)-1-(4-fluorophenyl)-3-{3-[3-(trifluoromethyl)phenyl]pyrrolidin-1-yl}propan-1-one O-methyloxime;

(1Z)-1-(4-fluorophenyl)-3-{3-[3-(trifluoromethyl)phenyl]pyrrolidin-1-yl}propan-1-one O-methyloxime;

1-(4-fluorophenyl)-3-[3-(2-methoxyphenyl)pyrrolidin-1-yl]propan-1-one O-methyloxime;


(1E)-1-(4-fluorophenyl)-3-[3-(3-methoxyphenyl)pyrrolidin-1-yl]propan-1-one O-methyloxime;

(1Z)-1-(4-fluorophenyl)-3-[3-(3-methoxyphenyl)pyrrolidin-1-yl]propan-1-one O-methyloxime;

(1E)-1-(4-fluorophenyl)-3-[3-(4-methoxyphenyl)pyrrolidin-1-yl]propan-1-one O-methyloxime; and

(1Z)-1-(4-fluorophenyl)-3-[3-(4-methoxyphenyl)pyrrolidin-1-yl]propan-1-one O-methyloxime.

76. (Withdrawn) The compound according to claim 70 wherein R₃ is



77. (Withdrawn) The compound according to claim 76 wherein

R₂ is aryl; and

R₄ is aryl.

78. (Withdrawn) The compound according to claim 76 wherein

R₂ is aryl wherein the aryl is selected from the group consisting of naphthyl and phenyl wherein the phenyl is substituted with 0, 1, or 2 substituents independently selected from the group consisting of alkyl, cyano, and halogen; and

R₄ is aryl wherein the aryl is phenyl substituted with 0 or 1 substituent selected from the group consisting of alkoxy, cyano, and haloalkyl.

79. (Withdrawn) The compound according to claim 78 selected from the group consisting of

1-(4-fluorophenyl)-3-(3-phenylpiperidin-1-yl)propan-1-one O-methyloxime;

1-phenyl-3-(3-phenylpiperidin-1-yl)propan-1-one O-methyloxime; and

1-(4-chlorophenyl)-3-(3-phenylpiperidin-1-yl)propan-1-one O-methyloxime.

80. (Withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (II) in combination with a pharmaceutically acceptable carrier.

81. (Withdrawn) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (II) or a pharmaceutically acceptable salt or prodrug thereof in combination with a pharmaceutically acceptable carrier.

82. (Withdrawn) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (II) or a pharmaceutically acceptable salt or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.

83. (Withdrawn) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (II) or a pharmaceutically acceptable salt or prodrug thereof in combination with an adrenergic receptor antagonist.


84. (Withdrawn) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (II) or a pharmaceutically acceptable salt or prodrug thereof in combination with a dopamine agonist.

85. (Withdrawn) A method of treating male erectile dysfunction in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (II) or a pharmaceutically acceptable salt or prodrug thereof.

86. (Withdrawn) A method of treating female sexual dysfunction in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (II) or a pharmaceutically acceptable salt or prodrug thereof.

87. (Withdrawn) A method of treating cardiovascular disorders, attention deficit hyperactivity disorder, Alzheimer's disease, drug abuse, Parkinson's disease, schizophrenia, anxiety, mood disorders or depression in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (II) or a pharmaceutically acceptable salt or prodrug thereof.

88. (Withdrawn) A method of treating sexual dysfunction in a mammal comprising administering to said mammal in need of such treatment a therapeutically effective amount of a compound of formula (III)



(III)

or a pharmaceutically acceptable salt or prodrug thereof, wherein


X is selected from the group consisting of O and NR_A ;

R_A is selected from the group consisting of hydrogen and alkyl;

R_1 is selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkynyl, arylalkyl, cyanoalkyl, cycloalkyl, haloalkyl, and hydroxyalkyl;

R_2 is selected from the group consisting of aryl, arylalkyl, heteroaryl, and heteroarylalkyl;

R_3 is



R_4 is aryl;

L is alkylene substituted with 0 or 1 substituent selected from the group consisting of alkoxy, alkoxyamino, hydroxy, and hydroxyiminoaryl;

R_B is selected from the group consisting of hydrogen and alkyl;

Z is selected from the group consisting of C and CH ; and

--- is absent or a single bond provided that when Z is C then --- is a single bond.

89. (Withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (III) in combination with a pharmaceutically acceptable carrier.

90. (Withdrawn) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (III) or a pharmaceutically acceptable salt or prodrug thereof in combination with a pharmaceutically acceptable carrier.

91. (Withdrawn) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (III) or a pharmaceutically acceptable salt or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.

92. (Withdrawn) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (III) or a pharmaceutically acceptable salt or prodrug thereof in combination with an adrenergic receptor antagonist.

93. (Withdrawn) A method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (III) or a pharmaceutically acceptable salt or prodrug thereof in combination with a dopamine agonist.

94. (Withdrawn) A method of treating male erectile dysfunction in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (III) or a pharmaceutically acceptable salt or prodrug thereof.

95. (Withdrawn) A method of treating female sexual dysfunction in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (III) or a pharmaceutically acceptable salt or prodrug thereof.

96. (Withdrawn) A method of treating cardiovascular disorders, inflammatory disorders, attention deficit hyperactivity disorder, Alzheimer's disease, drug abuse, Parkinson's disease, schizophrenia, anxiety, mood disorders or depression in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (III) or a pharmaceutically acceptable salt or prodrug thereof.